Pioneering the development of engineered IgM antibodies
Cancer Immunotherapy β’ Engineered Therapeutics β’ Engineered IgM Antibodies β’ Infectious Disease β’ Autoimmunity
201 - 500
π° $200M Post-IPO Equity on 2022-03
June 6
π’ In-office - Bay Area
β° Full Time
π΄ Lead
π·ββοΈ Project Manager